1 The EIC Accelerator Project

The EIC Accelerator program is a prominent funding initiative under the European Innovation Council (EIC), designed to support innovative small and medium-sized enterprises (SMEs) and startups in their efforts to develop and scale breakthrough technologies. This program particularly emphasizes deep-tech innovations, which often require significant investment and time to reach the market. The EIC Accelerator offers a unique financial structure known as "Blended Finance," combining grants and equity investments to provide a comprehensive funding solution.

Funding Structure

The EIC Accelerator provides funding through a dual approach: grants and equity investments.

Purpose and Impact

The EIC Accelerator serves a vital role in the European DeepTech and startup ecosystem by fostering innovation and promoting the commercialization of cutting-edge technologies. By offering substantial financial resources and support, the program enables startups to overcome common barriers such as high development costs and market entry challenges. The EIC Accelerator not only facilitates access to funding but also encourages collaboration with private investors, enhancing the chances of successful scaling and market adoption.

Moreover, the program is instrumental in aligning innovation with societal needs, particularly in sectors such as healthcare, sustainability, and digital transformation. This alignment fosters economic growth and positions Europe as a leader in technological advancements.

Case Study: Omini and the CardioCap Project

Omini, a French startup, emerged as a notable winner of the EIC Accelerator program with its innovative project, CardioCap. This initiative focuses on developing the first heart failure therapy management point-of-care device equipped with multiplex and multimodal sensors.

Technology Overview

CardioCap represents a groundbreaking advancement in heart failure management, which is a pressing health issue affecting millions globally. The device integrates multiple sensors capable of assessing various physiological parameters simultaneously, enabling comprehensive monitoring of patients’ heart health.

The technology behind CardioCap leverages advanced sensor technologies and data analytics to provide real-time insights into a patient’s cardiovascular status. By employing multiplexing, the device can perform several measurements at once, such as heart rate, blood pressure, and other vital signs, enhancing the efficiency of patient care.

The multimodal aspect of CardioCap allows for the integration of different types of data, providing a holistic view of a patient’s condition. This capability is essential for clinicians, as it supports timely decision-making and personalized treatment plans, ultimately improving patient outcomes.

Furthermore, the portability of CardioCap positions it as a point-of-care solution, making it accessible for use in various settings, including hospitals, clinics, and even home care situations. This accessibility is crucial in managing heart failure, as timely interventions can significantly reduce hospital readmissions and improve quality of life for patients.

Conclusion

Omini’s CardioCap project exemplifies the transformative potential of the EIC Accelerator program in the startup ecosystem. By securing funding through the EIC's blended finance model, Omini not only enhances its development capabilities but also positions itself for substantial impact in the healthcare sector. The innovative nature of CardioCap highlights the importance of integrating advanced technology in managing chronic health conditions, paving the way for more effective and personalized patient care solutions in Europe and beyond.

2 The Funding Rounds

Omini (ominilabs.com) – Financing, Funding Rounds, and Investor Information Since EIC Accelerator Award

Omini is a French startup that won EIC Accelerator funding in the March 2024 call. Details below summarize its financing activity, funding rounds, timing and amounts, investor involvement, company valuation data, and exit event information since receiving the EIC grant.

Financing Raised

• In July 2024, Omini received a €2.5 million grant from the European Innovation Council (EIC) as part of the March 2024 EIC Accelerator round.
• No public records indicate additional private fundraising or equity rounds for Omini during this period.
• There is no evidence of blended finance (grant plus equity) being awarded to Omini; only a grant allocation is referenced.

Funding Rounds: Timing and Amounts

Date	Round Type	Amount	Source
Jul 2024	Grant (EIC)	€2.5 million	European Innovation Council

There are no disclosures of subsequent private investment rounds or venture capital-led financings since July 2024.

Investor Information

• The primary investor identified post-EIC award is the European Innovation Council via its competitive selection process.
• There are no disclosed venture capital firms or angel investors participating in additional funding rounds for Omini during this period.

Related Funding Events

• The March 2024 EIC Accelerator call was highly competitive across Europe with more than €400 million distributed among selected companies using grants and blended finance.
• For Omini specifically, only non-dilutive grant support from the EIC has been publicly confirmed.

Company Valuations

• No public sources document an explicit post-money valuation for Omini following its July 2024 funding event.
• Unlike some higher-profile recipients that report valuations tied to large equity raises or Series A/B rounds, there is no indication that such valuation events have occurred for Omini up to May 6th, 2025.

Exit Events: IPOs/Buyouts/Acquisitions

• As of May 6th, 2025:
• There have been no reported exit events involving IPOs (Initial Public Offerings), buyouts by larger firms/corporates, or acquisitions related to Omini.
• The company remains independent with continued support from public innovation programs within France’s entrepreneurial ecosystem.

Summary Table

Event	Date	Details
EIC Grant Awarded	Jul 2024	€2.5M non-dilutive grant
Additional VC Rounds?	N/A	None publicly disclosed
Known Investors	Jul 2024	European Innovation Council
Company Valuation	N/A	Not publicly available
Exit Events	N/A	None as of May 6th, 2025

Ongoing monitoring may be required for future developments regarding further financing activity or potential exit strategies beyond this reporting window.

Sources: - OMINI company information, funding & investors

• OMINI company information on Dealroom.co
• Two X start-ups receive EIC funding - École polytechnique
• EIC Accelerator March 2024 Results: A Detailed Analysis

3 The Press Releases

Omini, a French company, received the EIC Accelerator funding in March 2024 after submitting its Step 2 proposal and successfully passing the Step 3 interview on March 13, 2024. However, specific details about Omini's business activities, technological advancements, partnerships, patents, or press releases are not readily available from the search results.

Given the nature of the EIC Accelerator funding, Omini likely received support for innovative projects, possibly involving deep-tech or high-impact ventures. The EIC Accelerator program is designed to foster groundbreaking innovations in Europe by providing financial support through grants, equity investments, or a combination of both.

For additional information about Omini, including press releases or updates, visiting their official website (ominilabs.com) might provide more insights into their recent developments and achievements since receiving the EIC funding.

Sources

• EIC Accelerator: Statistics and Results from the March 2024 call
• Latest EIC Accelerator Results
• EIC Accelerator March 2024 Results
• Two X start-ups receive EIC funding

4 The Technology Advancements

Current Capabilities and Advancements of Omini from France

Current Capabilities

At present, there is no publicly available information specifically about the company Omini from France, including their current capabilities or advancements since they received the EIC Accelerator funding in March 2024.

Advancements Since EIC Accelerator Funding

Since the EIC Accelerator funding in March 2024, there are no detailed reports or updates available regarding Omini's advancements, improvements in technology, or presentation of new features. The EIC Accelerator typically supports innovative ventures, but specific details about Omini's progress are not publicly disclosed.

Market Demonstration

There is no information available on whether Omini has demonstrated their technology with customers, or if they have engaged in any pilots, clinical trials, or similar activities since receiving the funding.

New Patents, Scientific Studies, or Clinical Trials

No new patents, scientific studies, or clinical trials related to Omini have been reported or published since they received the EIC Accelerator funding.

Given the lack of specific data on Omini, it is not possible to provide a detailed analysis of their advancements or activities post-funding.

Sources:

• No specific sources are available detailing Omini's activities or advancements.
• For general information on the EIC Accelerator, see:
• EIC Accelerator March 2024 Results
• Latest EIC Accelerator Results

5 The Partnerships and Customers

Omini's Strategic Partnerships and Market Positioning Post-EIC Accelerator Funding

Omini, a Paris-based health tech startup specializing in multiplexed blood testing for chronic disease management, has focused on advancing its sensor-based diagnostic platform since securing EIC Accelerator funding. While specific customer names remain undisclosed, the company's partnerships and technological milestones highlight its growth trajectory.

Key Partnerships & Collaborations

• Industrial & Academic Alliances: Omini collaborates with manufacturing partners (unnamed in public records) to finalize sensor production processes and develop its portable reader device.
• Regulatory & Clinical Networks: The company is engaged with clinical institutions for performance studies using human samples ahead of planned trials in heart failure management.

Technological Advancements

The EU-approved electrochemical sensor enables simultaneous measurement of 4–10 biomarkers from a single blood sample, positioning Omini as a leader in decentralized diagnostics. This technology reduces healthcare burdens by enabling at-home monitoring, particularly for heart failure patients—a market segment affecting over 10 million people in the EU.

Scaling Strategy

Omini’s focus includes:

• Manufacturing Validation: Streamlining test strip production to ensure affordability and scalability.
• Fundraising Efforts: Securing capital for clinical trials to validate its platform’s efficacy in real-world settings.

While recent announcements do not disclose new customers post-EIC award, Omini’s patent portfolio and emphasis on industrialization suggest prioritization of B2B partnerships with healthcare providers and medical device distributors. The company aims to establish itself as a standard-of-care solution for chronic disease monitoring through automation-friendly diagnostics.

---

Sources

• Omini receives EU patent approval for electrochemical based sensor
• Fabrication of wearable sensors with computerized embroidery (Conference Programme)

6 The Hiring and Company Growth

Omini's Team Dynamics and Growth Post-EIC Accelerator Funding Omini, a French healthtech company specializing in sensor-based chronic disease management, has positioned itself as an emerging innovator in precision medicine. While specific hiring metrics post-March 2024 EIC Accelerator win are not publicly detailed, available data and strategic indicators provide insights into its operational scale and growth trajectory.

• Current headcount: Listed as under 25 employees pre-funding, though post-accelerator expansion likely remains undisclosed.
• Team composition: Includes scientists, researchers, and a Director of Maintenance, with an emphasis on multidisciplinary expertise for product development.
• Hiring focus: Likely prioritizing R&D roles to advance its patented blood-testing ecosystem (strips, reader device, and app). Chronic disease management requires specialized talent in biosensors, data analytics, and regulatory compliance—areas critical to scaling production and clinical validation.
• Growth drivers: EIC funding typically accelerates commercialization efforts. For Omini, this could involve expanding manufacturing capabilities or securing partnerships for its near-patient diagnostic tools.

No recent leadership changes are reported since the March 2024 funding milestone. The company’s emphasis on "empowering patients through transformative technologies" suggests upcoming hires may target commercialization specialists or regulatory affairs experts to navigate EU medical device approvals.

---

Sources

Omini - ZoomInfo Profile

7 The Media Features and Publications

Omini: Media Coverage and Public Engagement Following EIC Accelerator Success

Omini, a France-based deep-tech company, secured EIC Accelerator funding in the March 2024 cut-off, though specific details about its award remain limited in publicly available sources. Below is a synthesis of verified media features and engagements related to the company:

Media Features and Publications

While no direct articles naming Omini were identified in available datasets, the company’s affiliation with École Polytechnique’s X-Novation Center positions it within a network of high-profile academic and technological ecosystems. The absence of explicit media coverage suggests potential undisclosed or niche publications not indexed in general search results.

Podcasts and Interviews

No podcasts or interviews featuring Omini’s team were found in the analyzed data. However, as an EIC Accelerator winner, the company may engage with EU innovation platforms or industry-specific channels for promotional activities post-funding.

Conferences and Events

• X-Novation Center: Omini was housed at this incubator during 2019–2020, likely participating in associated demo days or pitch events.
• EIC-Sponsored Events: As a grant recipient, Omini could leverage EIC-organized networking forums (e.g., InnovFest 2024) to showcase its technology, though specific participation remains unconfirmed.

Public Engagements

The company has been recognized through academic awards such as the 2019 Gerondeau-Safran Prize and X-Grant Silicon Valley 2020, indicating prior visibility within technical communities. Post-EIC funding announcements might amplify its public outreach efforts across EU innovation channels.

---

Sources

• EIC Accelerator Results – March 2024 Cut-off
• Two X Start-ups Receive EIC Funding